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httpcense.Abstract Background: Chronic obstructive pulmonary disease (COPD) patients were found to
have cerebral metabolic abnormalities. Proton magnetic resonance spectroscopy (1HMRS) is a sen-
sitive technique that detects metabolic changes of the brain.
Objective: To study the cerebral metabolic changes in COPD patients using 1H MRS.
Methods: This study was carried-out on twenty symptomatic COPD patients (16 male and 4
female) and age matched group of 20 healthy controls (11 male and 19 female). Pulmonary function
tests, respiratory muscle strength, resting arterial blood gases, and 1H MRS of the brain were car-
ried out on all subjects. The parieto-temporal and occipital regions were localized for 1H MRS. The
metabolic ratios of N-acetyl aspartate to creatine (NAA/Cr) and choline to creatine (Cho/Cr) were
calculated by the single voxel technique.
Results: In comparison with healthy control subjects, the mean values of Cho/Cr in COPD
patients were lower in parieto-temporal and occipital areas (0.99 ± 0.21 vs. 1.10 ± 0.31;
P= 0.22) (0.81 ± 0.26 vs. 0.88 ± 0.21; P= 0.37), respectively while, the mean values of NAA/
Cr in COPD patients were higher in both parieto-temporal and occipital areas of the brain
(1.82 ± 0.35 vs. 1.68 ± 0.22; P= 0.14) (1.59 ± 0.31 vs. 1.39 ± 0.39; P= 0.08), respectively. In
COPD patients, signiﬁcant positive correlations were observed between maximal expiratory pres-
sure (MEP) and NAA/Cr in parieto-temporal area of the brain.
Conclusions: The cerebral metabolites, arterial blood gases, respiratory muscle strength, and pul-
monary function tests are altered in symptomatic COPD patients. 1H MRS is a non invasive tech-
nique that detects cerebral metabolic changes in COPD patients.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.300940; fax: +20 482233521.
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Chronic obstructive pulmonary disease (COPD) affects up to
600 million people worldwide and is currently one of the major
causes of respiratory morbidity and mortality [1]. COPD is notis. Production and hosting by Elsevier B.V.
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tation of air ﬂow, shortness of breath, cough and expectora-
tion, but also by adverse effects on brain function [2].
Exacerbations of COPD accounted for over half of all acute
medical admissions for respiratory diseases [3]. Although
COPD is a slowly progressive disease, acute infective exacerba-
tions are associated with worsening hypoxia, hypercapnia, and
respiratory acidosis [4]. Normal cerebral cell function is
critically dependent on intracellular energy metabolism via
oxidative phosphorylation and the production of adenosine
triphosphate (ATP) [5]. (1H MRS) is a sensitive technique that
detects metabolic changes of the brain. Using 1H MRS differ-
ent metabolites present in the brain can be measured. They are,
N-acetyl aspartate (NAA), total creatine, choline containing
compound (cho), glutamate, glutamine, aspartate, alanine,
myo-inositol, lactate and glucose [6]. NAA is a neuronal mar-
ker the concentration of which decreases with neuronal cell
death. It is an intraneuronal molecule and it is found only in
neurons and axons of the mature brain. It is reduced in many
brain disorders, in the presence of neuronal and/or axonal loss
or dysfunction, such as infarcts, dementia, brain tumors, hyp-
oxic encephalopathy and multiple sclerosis [7,8]. Cho is associ-
ated with myelination, Choline containing compounds are an
integral part of the neuronal membranes. Their signal strength
on 1H MRS is an indicator of the phospholipid metabolism in
the brain [9]. Cr consists of Cr and phosphocreatine, and it
participates in energy metabolism. Cr is assumed to be a rela-
tively stable brain metabolite both in normal and pathological
conditions; it is often used as an internal standard in the
in vivo evaluation of relative concentrations of metabolites
[10,11]. Hydrogen 1 (1H) magnetic resonance (MR) spectros-
copy enables noninvasive quantiﬁcation of in vivo metabolite
concentrations in the brain. It has proved to be a powerful
addition to the clinical assessment tools for numerous patho-
logic conditions, including epilepsy, multiple sclerosis, stroke,
cancer, and metabolic diseases [12]. It has been approved by
the U.S. Food and Drug Administration and is widely used
for the evaluation of the brain and the prostate gland [13].
In this study, we suggest that cerebral metabolism may be dis-
turbed in COPD patients due to chronic hypoxia/hypercapnia
and this may have an inﬂuence on the levels of cerebral metab-
olites. This may have some clinical signiﬁcance.Subjects and methods
Twenty symptomatic COPD patients and age matched group
of 20 healthy control subjects were recruited from Chest and
Radiology Departments Menouﬁya University Hospital
Egypt, from October 2012 to January 2013. COPD was de-
ﬁned as evidence of chronic and generalized air-ﬂow limitation
(FEV1 < 80% predicted and FEV1/FVC < 70%) with long-
term variability in FEV1 or peak expiratory ﬂow rate of
<20% and acute B2-agonist reversibility of <15% [14]. No
patient had an acute exacerbation of COPD (deﬁned as hospi-
tal admission or prescription of antibiotics/systemic corticoste-
roids by a general practitioner) over 3 months prior to the
study. Patients with other, coexistent pulmonary diseases, con-
gestive heart failure, cirrhosis, dementia, and recent or old
stroke, and those with claustrophobia, cardiac pacemakers,
and ferromagnetic implants were excluded. The control sub-
jects were asymptomatic, healthy nonsmokers, and were takingno medications. All subjects gave written informed consent,
and ethical approval for the study was obtained from the local
ethics committees. Measures of pulmonary function included
spirometry, pulse oximetry at rest and change during a 6-min-
ute walk, and distance walked [15], arterial blood gas measure-
ments and respiratory muscle strength were done on the day of
the study for all patients. The MRS examination requires an
obligatory period during which each subject lies ﬂat within
the bore of the magnet, which presents technical difﬁculties
for COPD patients. Our study protocol was therefore intended
to minimize the time in the magnet; it was not possible to mea-
sure absolute concentrations of metabolites in mmol/g wet
weight of tissue in the present study because absolute quanti-
tation of metabolites with reference to a known concentration
of an external reference standard requires further sequences.
This would have unavoidably prolonged the examination time
beyond that which was ethically permissible and practically
possible for the patient population studied.
Pulmonary function test and respiratory muscle strength
Pulmonary function including forced vital capacity (FVC),
Forced expiratory volume in the ﬁrst second (FEV1), peak
expiratory ﬂow rate (PEFR) and FEV1/FVC was measured
by spirometer according to ATS criteria. Using severity classi-
ﬁcation of COPD Global initiative for chronic obstructive lung
disease guidelines (GOLD), via measurement of FEV1 as per-
cent predicted. IIa (FEV1 <50–79% predicted), IIb (FEV1
<30–49% predicted), and III (FEV1 <30% predicted) were
characterized in moderate and severe COPD patients. Clinical
assessment of the global function of respiratory muscle was
performed by measuring maximal inspiratory and expiratory
mouth pressure. Maximal static inspiratory (MIP) and maxi-
mal expiratory pressure (MEP) were measured in sitting posi-
tion. The MIP was measured near residual volume and MEP
was measured near total lung capacity. Best of three satisfac-
tory readings was taken for analysis.
1H magnetic resonance spectroscopy (MRS) of the brain
The 1H MRS was carried out using a 1.5 Tesla MRI scanner
(Toshiba Excelart Vantage). Spectroscopy was performed fol-
lowing a routine brain MRI analysis, and the T2-weighted
images were used for localization. Using these images well-de-
ﬁned regions of the brain namely, parieto-temporal and occip-
ital regions were localized for 1H MRS (Fig. 1). The single
voxel method was employed using sequence PRESS at an
echo-time (TE) of 136 ms and with a repetition time (TR) of
2000 ms, ﬁeld of view 2, matrix: 1 · 1024 was used for 1H
MRS. The metabolic ratios NAA/Cr and Cho/Cr were calcu-
lated by integrating area under each peak. One experienced
MRS operator undertook the careful placement of the locali-
zation-voxel in the same region for all subjects, thereby
increasing the consistency of region selection see (Fig. 2).
Results
The base line clinical characteristics are presented in Table 1.
The mean age of COPD patients was 59.30 ± 8.12 years.
There were 4/20 (20%) female and 16/20 (80%) male. All
COPD patients had dyspnea on exertion. 15/20 (75%) were
BA
Figure 1 MRI of the brain in axial plane in a patient with COPD showing localization of voxel in (A) left occipital and (B) left parieto-
temporal region.
BA
Figure 2 MRI of the brain in axial plane in control showing localization of voxel in (A) left occipital and (B) left parieto-temporal
region.
Table 1 Distribution of the studied groups regarding their demographic characteristics, ABG, PFT (spirometry and 6MWT),
respiratory muscle strength (MIP and MEP) and brain metabolites.
Patients (n= 20) Controls (n= 20) t Test P value
Mean ± SD Mean ± SD
Age 59.30 ± 8.12 58.65 ± 7.63 0.26 0.796
Gender: M/F 16 (80%)/4 (20%) 11 (55%)/9 (45%) 2.85* 0.091
PO2 63.9 ± 3.5 89.5 ± 7.5 6.65 <0.001
PCO2 49.9 ± 13.2 37.3 ± 8.1 3.64 <0.001
Arterial PH 7.40 ± 0.01 7.42 ± 0.03 2.83 0.008
FEV1 39.5 ± 12.4 83.3 ± 13.6 10.64 <0.001
PEFR L/min 204 ± 66 408 ± 92 8.06 <0.001
FVC 42.7 ± 12.9 83.8 ± 10.7 10.97 <0.001
FEV1/FVC 68.9 ± 7.9 76.9 ± 8.3 3.12 <0.01
MIP 4.2 ± 0.7 7.4 ± 1.6, 8.19 <0.001
MEP 4.6 ± 0.56 7.5 ± 1.7 7.19 <0.001
6 MWD feet 922 ± (262) 1545 ± (196) 8.52 <0.001
SpO2 resting 96.0 ± (2.2) 98.1 ± (1.5) 3.53 0.001
SpO2 minimum during 6MW 88.0 ± (3.1) 94.6 ± (1.7) 8.35 <0.001
Parieto-temporal NAA/Cr 1.82 ± 0.35 1.68 ± 0.22 1.51 0.139
Parieto-temporal Cho/Cr 0.99 ± 0.21 1.10 ± 0.31 1.24 0.223
Occipital NAA/Cr 1.59 ± 0.31 1.39 ± 0.39 1.77 0.084
Occipital Cho/Cr 0.81 ± 0.26 0.88 ± 0.21 0.89 0.378
*
Q star related to qui- square.
Value of Proton Magnetic Resonance Spectroscopy of brain to study the cerebral metabolic abnormalities in COPD 75current smokers. 8/20 (40%) patients were being treated with
theophylline and inhaled corticosteroid (ICS), 3/20 (15%) with
diuretics, and 9/20 (45%) patients with ipratropium bromide
inhaler. The degree of air way obstruction was moderate IIa
in 6/20 (30%) patients, moderate IIb in 7/20 (35%) patients,
and severe in another 7/20 (35%) patients. All patients hadPaO2 of >60 mm Hg at the resting state. The measured
PCO2 for the patients was >45 mm Hg in 10/20 (50%) pa-
tients, and <45 mm Hg in another 10/20 (50%) patients. 9/
20 (45%) COPD participants were on long-term continuous
O2 therapy. The mean values of PCO2 were (49.9 ± 13.2 vs.
37.3 ± 8.1 mm Hg) in COPD patients compared with healthy
Table 2 Correlation between concentration of brain metabolites by MRS and different clinical variables in patients with COPD.
Age PO2 PCO2 FEV1 FVC FEV1/FVC
Parieto-temporal NAA/Cr 0.238
P= 0.313
0.187
P= 0.431
0.389
P= 0.090
0.122
P= 0.607
0.114
P= 0.632
0.025
P= 0.918
Cho/Cr 0.294
P= 209
0.070
P= 0.771
0.254
P= 0.280
0.082
P= 0.733
0.050
P= 0.833
0.335
P= 0.148
Occipital NAA/Cr 0.348
P= 0.133
0.127
P= 0.592
0.063
P= 0.791
0.064
P= 0.790
0.083
P= 0.729
0.140
P= 0.573
Cho/Cr 0.410
P= 0.072
0.029
P= 0.903
0.127
P= 0.593
0.053
P= 0.824
0.004
P= 0.986
0.033
P= 0.891
6 MWD feet SpO2 resting SpO2 minimum during 6MW MIP MEP
Parieto-temporal NAA/Cr 0.13
P= 0.958
0.362
P= 0.116
0.402
P= 0.079
0.191
P= 0.419
0.66
P= 0.002
Cho/Cr 0.161
P= 0.497
0.216
P= 0.360
0.038
P= 0.875
0.189
P= 0.424
0.433
P= 0.056
Occipital NAA/Cr 0.638
P= 0.002
0.380
P= 0.099
0.184
P= 0.439
0.380
P= 0.098
0.249
P= 0.290
Cho/Cr 0.433
P= 0.057
0.360
P= 0.118
0.441
P= 0.052
0.018
P= 0.940
0.274
P= 0.242
76 R. El-Helbawy et al.control subjects. In COPD participants FEV1/FVC, FEV1,
and FVC values were (68.9 ± 7.9), (39.5 ± 12.4), and
(42.7 ± 12.9) of predicted, respectively. While in controls
were, (83.3 ± 13.6), (83.8 ± 10.7), and (76.9 ± 8.3) of pre-
dicted, respectively. The mean values of MIP were (4.2 ± 0.7
vs. 7.4 ± 1.6, P< 0.001) and MEP (4.6 ± 0.56 vs.
7.5 ± 1.7, P< 0.001) in COPD patients compared to healthy
control. Groups were well matched across demographic char-
acteristics and showed the expected difference in the main lung
disease related predictor (independent) variables. Statistically
signiﬁcant differences between control and the whole COPD
group were found for several measures (I) pulmonary function
test: FEV1, FVC, FEV1/FVC, PEFR, 6MW distance, resting
arterial oxygen saturation (Spo2) and minimal arterial oxygen
saturation during 6MWT. (II) Arterial blood gases: arterial
oxygen tension (PO2) and arterial carbon dioxide tension
(PCO2). (III) Respiratory muscle strength: MIP and MEP.
Group comparisons for key outcome (dependent) variable
are shown in Table 2, where the mean values of NAA/Cr
and Cho/Cr in parieto-temporal area in COPD patients were
1.82 ± 0.35 and 0.99 ± 0.21, respectively. The mean values
of NAA/Cr and Cho/Cr in occipital area in COPD patients
were 1.59 ± 0.31 and 0.81 ± 0.26, respectively (Table 1).
Compared with healthy control subjects, the mean values of
Cho/Cr in COPD patients were lower in parieto-temporal
and occipital areas (0.99 ± 0.21 vs. 1.10 ± 0.31; P= 0.22)
and (0.81 ± 0.26 vs. 0.88 ± 0.21; P= 0.37), respectively.
However, this difference did not attain statistical signiﬁcance.
Compared with healthy control subjects, the mean values of
NAA/Cr in COPD patients were higher in both parieto-tempo-
ral and occipital areas (1.82 ± 0.35 vs. 1.68 ± 0.22; P= 0.14)
and (1.59 ± 0.31 vs. 1.39 ± 0.39; P= 0.08), respectively of
the brain. However, this difference did not attain statistical sig-
niﬁcance. There was a negative correlation between NAA/Cr
and po2, FEV1, FVC&FEV1/FVC and a positive correlation
between NAA/Cr and pCo2 in COPD patients. However
Cho/Cr and po2, FEV1, FVC&FEV1/FVC revealed a positivecorrelation, but there was a negative correlation between Cho/
Cr and pCo2 in COPD patients. While signiﬁcant positive cor-
relations were observed between MEP and NAA/Cr in parieto-
temporal area of the brain (r= 0.66, P< 0.05).
Signiﬁcant positive correlation between arterial PH and
PO2.
Signiﬁcant negative correlation between 6MWD feet and
NAA/Cr occipital.
Peaks were identiﬁed with known chemical shifts of NAA
at 2.02 ppm, Cr at 3.03 ppm and Cho at 3.22 ppm (Fig. 3).
The raw spectroscopic data were transferred to a computer
workstation and were processed by a special software.
A B
Figure 3 The spectrum obtained from COPD from the occipital (A) and parieto-temporal region (B) acquired at TE = 136 ms and
TR= 2000 ms.
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Impaired brain function has long been recognized as a compli-
cation of COPD [16]. Patients with mild to moderate hypoxia
have previously been found to have abnormalities on testing
for psychometric functions, activities of daily living, and elec-
troencephalography [17,18]. We therefore postulated abnor-
malities in brain bioenergetics in patients with chronic stable
hypoxia. The aims of the present study were to identify
changes in 1H MRS spectra obtained from the brains of pa-
tients with stable COPD, and to compare the results with
MR spectra from the same areas of the brain in healthy control
subjects. This study examined the brain dysfunction in a care-
fully selected group of COPD patients and matched controls,
using disease-speciﬁc measures of disease severity, disability,
and validated measures of neurochemical of brain integrity.
In the present work Cho/Cr cerebral metabolites in COPD pa-
tients were lower in both parieto-temporal and occipital areas
of the brain (0.99 ± 0.21 vs. 1.10 ± 0.31) and (0.81 ± 0.26 vs.
0.88 ± 0.21 P= 0.3), respectively, in comparison to healthy
control subjects. However, this difference did not attain statis-
tical signiﬁcance. While, a general non-signiﬁcant increase of
NAA/Cr cerebral metabolite was observed in similar areas of
the brain of COPD patients as compared to healthy control.
Cerebral metabolism was investigated with proton magnetic
resonance spectroscopy (MRS) using the multivoxel technique
in another study [19] which comprised 30 male patients, aged
45–70 years, with moderate level COPD and an aged matched
group of 30 healthy males as the control group. Karakas and
his colleagues [19] reported that the frontal and parietal white
matter in patients with COPD showed an overall reduction in
cerebral metabolites. The NAA/Cr, and Cho/Cr ratios of the
cerebral frontal and parietal white matter regions in the COPD
group were signiﬁcantly lower than the control group. The
ﬁndings of this study through the use of MRS conﬁrmed that
most patients with symptomatic COPD have cerebral meta-
bolic abnormalities. Sinha et al. [20] had investigated changes
in the cerebral metabolism of non diabetic and normo-lipidae-
mic patients with chronic obstructive pulmonary disease
(COPD) using 1H MRS, 28 symptomatic COPD patients
and 19 healthy controls. The mean values of NAA/Cr and
Cho/Cr in parieto-temporal area in COPD patients were
1.86 ± 0.54 and 0.77 ± 0.23, respectively. The mean values
of NAA/Cr and Cho/Cr in occipital area in COPD patients
were 1.75 ± 0.44 and 0.61 ± 0.25, respectively. Compared
with healthy control subjects, the mean values of Cho/Cr inCOPD patients were lower, both in parieto-temporal
(0.77 ± 0.23 vs. 0.89 ± 0.35; P= 0.17) and occipital
(0.61 ± 0.25 vs. 0.67 ± 0.08; P= 0.36) areas of the brain.
To evaluate the clinical signiﬁcance of cerebral metabolic
abnormalities in COPD patients Shim et al [7] using the
MRS, examined seventeen symptomatic COPD patients and
21 age-matched healthy volunteers, The mean FEV1 was
38 ± 10% predicted, the PaCO2 was 39 ± 7 mm Hg, and
the PaO2 was 89 ± 18 mm Hg, and these values did not exhi-
bit a statistical correlation with the levels of cerebral metabo-
lites. NAA, Cr, and Cho levels in parietal white matter (PWM)
were all signiﬁcantly lower in COPD patients than in control
subjects (P< 0.0125). They suggested that decreased in vivo
Cho levels indicate loss of myelin lipids or phospholipid
metabolism dysfunction. On the other hand, Borson et al.
[21] reported that frontal choline was signiﬁcantly higher in
oxygen dependent COPD subjects, consistent with evidence
of brain damage in this most impaired group. Neurochemical
measures of frontal choline were 3.96 ± 0.38, 3.30 ± 0.46
and 4.50 ± 0.71 in control, COPD and O2 dependent group
of COPD, respectively, whereas NAA or creatine revealed no
signiﬁcant statistical difference between different studied
groups. Elevation of frontal choline in oxygen-dependent
COPD patients is consistent with the work of Incalzi et al.
[25] using a different (perfusion) imaging approach. In that
comprehensive mapping study, substantial perfusion deﬁcits
were identiﬁed in frontal lobes and were most marked in oxy-
gen-dependent subjects. We propose that frequent oxygen
desaturation during everyday activity of COPD patients may
be a key mechanism underlying the damage to brain tissue re-
ﬂected in elevated brain choline. Similar choline elevations are
observed in systemic diseases secondarily associated with brain
tissue breakdown and cognitive impairment (Friedman et al.
[22], Forton et al. [23]), and appear to reﬂect damage to myelin
and increased turnover of neuronal membrane precursors
(Ross and Michaelis [24]). It is likely that increases in choline
in advanced hypoxemic COPD reﬂect such a combination of
membrane breakdown and turnover changes in the brain,
and that these are eventually manifested as white matter hyper-
intensities on structural imaging. Other spectroscopy ap-
proaches (eg, decoupled 31P MRS) to measure individual
constituents of the choline peak could be helpful in reﬁning
and further interpreting these results. In diseases in which there
is increased cell repair like in COPD, there is an increase in
choline resonance. This is because the normal equilibrium that
exists between cell membrane synthetic products (like phos-
78 R. El-Helbawy et al.phocholine) and breakdown products (like glycerophospho-
choline) is altered in favor of cell membrane synthesis. Under
these circumstances the cell membrane degradation products
would be recirculated into synthetic pathways, this would
therefore result in increasing choline resonance [26]. However,
Shim et al. [7] and Sinha et al. [20] studies, excluded oxygen
dependent subjects, participants were younger, analyses were
not adjusted for age and education, and the brain regions sam-
pled were different from those used in the previous study and
possibly less likely to be related to changes in mood and cog-
nition. Their results matched with our work as regards reduced
Cho/Cr metabolites in COPD patients. Although our study did
not establish causality, it is likely that the changes we observed
in cerebral bioenergetics in COPD patients were a consequence
of chronic changes in arterial blood gases. It is also unclear
whether these changes in cerebral bioenergetics are a conse-
quence of chronic hypoxia, hypercapnia, or both [28]. A study
by Alchanatis et al., [29] showed that patients with hypoxia in
obstructive sleep apnea and without a medical history of car-
diac disease or cardiovascular risk factors had signiﬁcantly de-
pressed NAA/Cr and Cho/Cr ratios, as well as a diminished
Cho concentration in brain white matter, when compared to
controls. This ﬁnding suggests that hypoxia may promote
brain metabolic impairment even in the absence of hypercap-
nia or other co-morbidities. Different pathophysiologic abnor-
malities associated with various diseases may induce their own
characteristic changes in the brain. Co morbid diseases such as
congestive heart failure (CHF), diabetes mellitus (DM),
Chronic liver diseases (CLD), and other risk factors like smok-
ing associated with COPD patients may have different effects
on the cerebral metabolites. In patients with DM, the cholin
level increases in both the parietal white matter and the occip-
ital gray matter, whereas a signiﬁcant reduction of NAA is
found in the parietal cortex [28]while chronic hepatic encepha-
lopathy, reduced the Cho levels in the cerebral parietal white
matter. Patients with CHF showed a more prominent decrease
of brain metabolites [28,29]. MR-based metabolomics had
ability in discriminating patients exposed to same risk factors,
smoking habit: 50 current smokers without COPD, COPD
smokers analyzed by a mean of MR. MR spectra of exhaled
breath condensate discriminate COPD patients from healthy
subjects in smoking habit related disease. Cerebral metabolites
were prominently reduced in COPD smoker than healthy smo-
ker. MR offers a powerful tool for assessing the evolution of
air way disease even in the presence of strong common factors
[30–32]. Neuronal cell death is generally considered to be an
irreversible process accompanying aging, and decreased levels
of NAA are reported frequently in healthy aged persons [30].
Mathur et al. [27] reported that there is an accumulation of
cerebral lactate and a reduction in N-acetyl aspartate in proton
MRS spectra in patients with COPD. Karakas and his col-
leagues [19], Shim et al. [7] and Sinha et al. [20] results were
matched with the previous results. In the present work
NAA/Cr ratio increased, however COPD participants were
younger, analyses were not adjusted for age. Also 9/20
(45%) were oxygen dependent subjects, it is not known
whether the spectroscopic abnormalities observed in hypoxic
patients are correctable with supplemental oxygen or, indeed,
are inducible in normal human subjects with controlled exper-
imental hypoxia and weather earlier oxygen supplementation,
could help to prevent irreversible brain damage in COPD pa-tients. The possibility of cerebral NAA restoration might be
expected using long term oxygen therapy for these COPD pa-
tients. Further studies are needed to conﬁrm whether these in-
creases represent actual neural regeneration. Also the brain
regions sampled in previous studies were different from those
used in the present study. This association in COPD patients
between blood pH and arterial PO2 suggests that at least as
far as these patients are concerned, the metabolites of anaero-
bic metabolism do have an impact on blood pH. In a hypoxic
intracellular environment, the cell relies chieﬂy on glycolysis
for ATP generation as both Kreb’s cycle and oxidative phos-
phorylation become inefﬁcient. With acceleration of glycolysis,
intracellular lactate is expected to accumulate. This is expected
to result in a decrease in blood pH as the cell becomes over-
whelmed with excess lactate. The linear relationship observed
between PaO2 and pH (although still within normal range)
in our study seems to support this notion. This ﬁnding sup-
ports our speculation that the switch to anaerobic metabolism
in hypoxic patients tends to result in lactate accumulation,
which is in turn buffered by cationic proteins. Patients with
chronic stable hypoxia seem to fully compensate for develop-
ing intracellular brain acidosis either through active ion trans-
ports of protons outside the cell [33,34] or by retention of
bicarbonate [35]. It is interesting to speculate that as hypoxia
increases, the ability of the neuron to buffer lactate, pump
out protons, and retain bicarbonate might fail, resulting in aci-
dosis. This may be the mechanism underlying the decompensa-
tion in cerebral function with agitation, confusion, and
ultimate unconsciousness that is characteristic of severe respi-
ratory failure. In the present work expected statistically signif-
icant differences in the main lung disease related predictor
(independent) variables between control and the COPD group
were found for several measures (I) pulmonary function test:
FEV1, FVC, FEV1/FVC, PEFR, 6MW distance, resting arte-
rial oxygen saturation (Spo2) and minimal arterial oxygen sat-
uration during 6MWT. (II) Arterial blood gases: PH, arterial
oxygen tension (PO2) and arterial carbon dioxide tension
(PCO2). (III) Respiratory muscle strength: MIP and MEP.
Tarrega et al. [13] stated that patients with severe COPD be-
came chronically hypoxemic and hypercapnic. Delclaux et al.
[36] posted that, patients with COPD in chronically stable con-
ditions expected to have an increased oxygen alveolar-arterial
gradient, and therefore lowered PaO2 compared with healthy
subjects. Moderate COPD patients were hypoxemic only dur-
ing modest exercise, and as the disease worsened, they were un-
able to exercise at all. They also reported a persistent,
irreversible low FEV1 which was the most characteristic objec-
tive ﬁnding in COPD. Clinical assessment of the global func-
tion of the respiratory muscle was performed by measuring
maximal inspiratory and expiratory mouth pressure, although
these measurements were very effort dependent. They stated
that patients with COPD had an impaired value of MIP and
MEP. Gosselink and his colleagues in a meta-analysis included
32 randomized controlled trials on the effects of inspiratory
muscle training in COPD they announced that maximal inspi-
ratory muscle strength was reduced (+7 cm H2O) and a signif-
icant improvement was found in MIP, endurance time and
walking distance after training modality (strength or endur-
ance training, added to general exercise training). Our data re-
vealed that, signiﬁcant negative correlations were observed
between MEP and NAA/Cr in parieto-temporal area of the
Value of Proton Magnetic Resonance Spectroscopy of brain to study the cerebral metabolic abnormalities in COPD 79brain (r= 0.66, P< 0.05) and between 6MW distance and
NAA/Cr in occipital area of the brain. These results were in
agreement with Shim et al. [7] and Sinha et al. [20] results.
In conclusion, the results of our study demonstrate that the
cerebral metabolism, pulmonary functions, arterial blood
gases and respiratory muscle strength are altered in symptom-
atic COPD patients. The present study offers insight into the
complex biochemical changes in the brains of patients with
moderate and severe COPD. Further work needs to be done
(with 31P MRS and 1H MRS) to correlate the cerebral bioen-
ergetic abnormalities in these patients with other evaluations
of cerebral function, and to directly measure levels of intracel-
lular brain lactate and PH. It is now possible to combine MRS
with near-infrared spectrophotometry in the same examination
in order to assess changes in cerebral blood ﬂow. Further stud-
ies should combine both modalities, since it is not known
whether the spectroscopic abnormalities observed in hypoxic
patients are correctable with supplemental oxygen or, indeed,
are inducible in normal human subjects with controlled exper-
imental hypoxia and hypercapnia. Correction of such cerebral
bioenergetic abnormalities with administered pharmacological
agents, independent of any changes in ventilatory status and
both in patients with stable COPD and patients with acute
exacerbation of this disease may pave the way for novel modal-
ities of therapy to support cerebral compensation in these pa-
tients. Routine identiﬁcation of episodic desaturation with
everyday activity, and/or sleep, and earlier oxygen supplemen-
tation, could help to prevent irreversible brain damage in
COPD patients. Further studies will be required to document
the mechanism and clinical signiﬁcance of cerebral metabolic
abnormalities in COPD patients and to conﬁrm the effect of
therapeutic interventions on the cerebral metabolism. Limita-
tion of this study: Small sample size technical difﬁculties for
COPD patients and inability to measure absolute concentra-
tions of cerebral metabolites were the main obstacles in the
present work.
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